For Healthcare Professionals

Bridging the nutrition gap during pregnancy.

Clinical evidence, safety data, and prescribing information on PARIVIT-F, a UNIMMAP MMS formulation aligned with WHO / UNICEF guidance.

The Challenge

Nutrition gaps during pregnancy.

Pregnancy dramatically increases a woman's nutritional needs, yet diet alone often cannot meet them. In LMICs, where many women are already micronutrient deficient before becoming pregnant, this gap can have life-threatening consequences.

Globally, two in three women of reproductive age have at least one micronutrient deficiency. Anemia, often caused by iron deficiency, affects 36% of pregnant women worldwide and increases the risk of postpartum hemorrhage, the leading cause of maternal mortality.

2 in 3
women of reproductive age with a micronutrient deficiency
36%
of pregnant women globally affected by anemia
12-14%
reduction in low birthweight with MMS vs IFA
8%
reduction in stillbirths with MMS vs IFA
UNIMMAP MMS

United Nations International Multiple Micronutrient Antenatal Preparation.

Developed in 1999 through collaboration between the World Health Organization (WHO), the United Nations University (UNU) and UNICEF, UNIMMAP MMS was tested in rigorous randomized controlled trials for safety and effectiveness. In 2021, it was added to the WHO Essential Medicines List, recognizing it as one of the most proven, cost-effective and safe interventions for pregnancy.

The MMS formulation provided by PARIVIT-F is consistent with the UNIMMAP formula and manufactured to international quality standards.

WHO EML 2021 21 clinical trials Since 1999
Proven Impact

What the evidence shows.

General
12-14%
Reduction in
Low birthweight
General
6-8%
Reduction in
Preterm births
General
8%
Reduction in
Stillbirths
General
13-19%
Reduction in
Very preterm births
Anemic mothers
19%
Reduction in
Low birthweight
Anemic mothers
29%
Reduction in
6-month infant mortality
Even more effective
in anemic and underweight pregnant women.
Adolescent girls
19%
Reduction in low birthweight

Adolescent girls receiving MMS during pregnancy see the same improved birth outcomes as adult mothers, supporting its use in this vulnerable population.

Compared with iron-folic acid alone.

Iron Optimization

Half the iron. Equal protection.

Multiple clinical trials and meta-analyses confirm that the 30 mg of iron in UNIMMAP MMS provides comparable results to the 60 mg in standard IFA, equally effective at protecting against maternal anemia and maintaining third-trimester hemoglobin levels.

A landmark iron dose analysis published in the Annals of the New York Academy of Sciences evaluated data from multiple global trials and confirmed this equivalence. The reason comes down to a synergistic nutrient design: co-formulated vitamins and minerals improve iron utilization and erythropoiesis.

Elemental iron per daily dose
30mg
MMS
PARIVIT-F · UNIMMAP
=
60mg
IFA
Standard iron-folic acid
Same protection against maternal anemia, with better tolerability.
Guidelines & Policy

Recommended by WHO, UNICEF and Pakistan's national strategy.

WHO EML 2021

UNIMMAP MMS tablets for antenatal use are included in the WHO Model List of Essential Medicines (2021).

Pakistan Maternal Nutrition Strategy 2022-2027

UNICEF and Pakistan endorse the transition from IFAS to MMS for every pregnant mother.

Highly Cost-Effective

A full pregnancy of PARIVIT-F costs approximately $14.89, far below Pakistan's per-capita GDP ($1,901), meeting the WHO very-cost-effective threshold.

Cost-Effectiveness

Highly cost-effective by WHO thresholds.

Cost-effectiveness of an intervention like MMS is measured against Disability-Adjusted Life Years (DALYs) averted. Under the WHO cost-effectiveness framework, if the cost per DALY averted is lower than the country's per-capita GDP, the intervention is classified as very cost-effective.

DALY
Disability-Adjusted Life Year

A measure of overall disease burden, the number of years of healthy life lost to illness, disability or early death. Interventions aim to avert DALYs.

Pakistan Per-Capita GDP
$1,901 (2025-26)

The WHO threshold for a "very cost-effective" health intervention in Pakistan.

PARIVIT-F Coverage
$14.89-$15.00

Full-pregnancy coverage per mother, far below the GDP threshold, meeting the highly cost-effective WHO classification.

Pakistan Maternal Nutrition Strategy 2022-2027

UNICEF and Pakistan have reflected the updated WHO / UNICEF recommendations in the national Maternal Nutrition Strategy, which specifically endorses the transition from IFAS to MMS. WHO and UNICEF further recommend the provision of MMS tablets to every pregnant mother, and emphasise local manufacture (PARIVIT-F) to ensure country-wide availability, so that whenever a pregnant woman has her ANC contact, she is offered or prescribed MMS instead of IFAS.

Clinical Review

Benefits across the full pregnancy journey.

A published review of clinical benefits and safety of Multiple Micronutrient Supplementation across preconception, pregnancy and lactation shows that using MMS throughout the entire pregnancy journey, rather than only in preconception and the first trimester, better supports maternal nutritional needs and the healthy development of the baby.

There is a clear need for more healthcare providers to recommend MMS at every stage of pregnancy. This simple, proven intervention works best when paired with a healthy, balanced diet where possible, and used under the guidance of a healthcare professional.

Read the full review
Technical Brief
MMS in Adolescents (LMICs)
25 September 2025 · MMS Technical Advisory Group

The MMS TAG released a new technical brief on MMS for adolescents in low- and middle-income countries. MMS is beneficial and safe for women during pregnancy, and global guidance supports its use in adolescent girls who are pregnant or breastfeeding, particularly in humanitarian settings.

  • 1 Pregnant adolescent girls, evidence shows MMS (vs IFA) improves birth outcomes, similar to results in adult pregnant women.
  • 2 Non-pregnant adolescents (girls and boys), MMS vs IFA can improve micronutrient status without differing in anemia-reduction impact.
Global Call for Healthcare Professionals

Join the WHO & UNICEF global initiative.

More than 25 years of evidence show that MMS provides the foundation for millions of pregnant women and their babies to live better, healthier lives. Whenever a pregnant woman has her ANC contact, she should be offered a MMS tablet instead of IFAS.

One tablet a day keeps mother and baby strong, PARIVIT-F community health campaign
Formulation Note

Why PARIVIT-F MMS contains 5 mcg (200 IU) of Vitamin D

For three primary historical and clinical reasons.

01

The historical "time capsule" effect (1999 standards)

The UNIMMAP formulation was established in 1999 during a joint workshop by UNICEF, the WHO, and the United Nations University. At that time, the US Institute of Medicine (now the National Academy of Medicine) and global bodies recognised the Adequate Intake (AI) / Recommended Dietary Allowance (RDA) for pregnant women as 5 mcg (200 IU) per day. Decades of extensive global clinical trials used this exact 1999 recipe. Because the combination proved highly successful at preventing low birth weight and preterm births, global health bodies kept the formula completely unchanged to preserve its proven clinical track record.

02

Formulated for general global backgrounds, not severe deficiency

UNIMMAP is designed as a foundational, one-size-fits-all public health supplement for low and middle income countries (LMICs). Dietary top-up: it assumes pregnant women will still receive a portion of their Vitamin D from environmental sunlight and background foods. Not a therapeutic cure: it was never designed to aggressively treat clinical Vitamin D deficiency. Modern, higher recommendations (such as 10 to 15 mcg) are target numbers intended to cover women who have zero sun exposure or severe baseline deficiencies.

03

Balanced interactions with other nutrients

Prenatal micronutrients function as an ecosystem. Vitamin D is essential for absorbing other minerals effectively. The 5 mcg dose provides enough baseline metabolic support to aid the absorption of the tablet's other core minerals (such as zinc, and calcium from the mother's diet) without causing gastrointestinal side effects or interfering with the absorption mechanics of the 30 mg of iron included in the tablet.

While modern regional guidelines in some high-income nations have since raised individual Vitamin D recommendations for pregnancy (often to 10 mcg / 400 IU or higher), the UNIMMAP formulation remains strictly standardised to its 1999 expert-consensus specifications. This consistency ensures that the rigorous clinical data supporting its efficacy, which eventually led to its inclusion on the WHO Model List of Essential Medicines, remains globally valid and replicable by open-access manufacturers.

Scientific Evidence

References

The clinical positioning of PARIVIT-F is grounded in the following peer-reviewed literature and WHO / UNICEF publications.

  1. 1 World Health Organization. Model List of Essential Medicines, 22nd List, 2021. Geneva: World Health Organization; 2021.
  2. 2 Gernand AD, Schulze KJ, Stewart CP, West KP Jr, Christian P. Micronutrient deficiencies in pregnancy worldwide: Health effects and prevention. Nat Rev Endocrinol. 2016;12(5):274-289.
  3. 3 Stevens GA, Beal T, Mbuya MNN, Luo H, Neufeld LM; Global Micronutrient Deficiencies Research Group. Micronutrient deficiencies among preschool-aged children and women of reproductive age worldwide: A pooled analysis of individual-level data from population-representative surveys. Lancet Glob Health. 2022.
  4. 4 Bourassa MW, Osendarp SJ, et al. Review of the evidence regarding the use of antenatal multiple micronutrient supplementation in low- and middle-income countries. Ann. N.Y. Acad. Sci. 2019;1444:6-21.
  5. 5 The World Health Organization. Global anaemia estimates, 2021.
  6. 6 Kominiarek et al. Nutrition recommendations in pregnancy and lactation. Med Clin North Am. 2017.
  7. 7 Prado E, et al. Maternal multiple micronutrient supplementation and other biomedical and socioenvironmental influences on children's cognition at age 9-12 years in Indonesia: Follow-up of the SUMMIT randomised trial. Lancet Glob. Heal. Feb 2017. E217-e228.
  8. 8 Smith ER, Shankar AH, Wu LS, et al. Modifiers of the effect of maternal multiple micronutrient supplementation on stillbirth, birth outcomes, and infant mortality: A meta-analysis of individual patient data from 17 randomised trials in low-income and middle-income countries. The Lancet Global Health. 2017 Nov 1;5(11):e1090-100.
  9. 9 Perumal N, et al. Impact of scaling up prenatal nutrition interventions on human capital outcomes in low- and middle-income countries: A modeling analysis. Am J Clin Nutr. 2021 Nov 8;114(5):1708-1718.
  10. 10 Keats EC, et al. Multiple-micronutrient Supplementation for Women during Pregnancy. Cochrane Database Syst. Rev. 2019, 3.
  11. 11 World Health Organization. WHO Antenatal Care Recommendations for a Positive Pregnancy Experience. Nutritional Interventions Update: Multiple Micronutrient Supplements during Pregnancy. 2020.
  12. 12 Wang D, Liu E, Perumal N, Partap U, Cliffer IR, Costa JC, et al. The effects of prenatal multiple micronutrient supplementation and small-quantity lipid-based nutrient supplementation on small vulnerable newborn types in low-income and middle-income countries: a meta-analysis of individual participant data. Lancet Glob Health. 2025;13:e298-308.
  13. 13 Gomes F, Adu-Afarwuah S, Agustina R, et al. Effect of prenatal multiple micronutrient supplementation compared with iron and folic acid supplementation on size at birth and subsequent growth through 24 mo of age: a systematic review and meta-analysis. The American Journal of Clinical Nutrition. April 2025.
  14. 14 Clinical Benefits and Safety of Multiple Micronutrient Supplementation (MMS) During Preconception, Pregnancy, and Lactation: A Review. pmc.ncbi.nlm.nih.gov/articles/PMC12603366
  15. 15 World Health Organization, UNICEF, & United Nations University. Composition of a multi-micronutrient supplement to be used in pilot programmes among pregnant women in developing countries (Report No. WHO/HDN/99.1). World Health Organization, 1999.
  16. 16 World Health Organization. Application for inclusion of multiple micronutrient supplement (MMS) on the WHO Model List of Essential Medicines for pregnant women. World Health Organization, 2021.
  17. 17 Bourassa MW, Osendarp SJ, Deal C, De-Regil LM, Johnston RB, Kariger P, Manger MS, McDonald CM, McLean J, Moore SE, Prado EL, Shah L, Sharma S, Suchdev PS, & Wegmüller R. Improving maternal nutrition: An open-access United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) monograph. Annals of the New York Academy of Sciences, 2020;1470(1):3-13.